{
    "Trade/Device Name(s)": [
        "ADVIA Centaur\u00ae Total hCG assay"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics, Inc.",
    "510(k) Number": "K200210",
    "Predicate Device Reference 510(k) Number(s)": [
        "K172322"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHA"
    ],
    "Summary Letter Date": "October 16, 2020",
    "Summary Letter Received Date": "October 20, 2020",
    "Submission Date": "October 16, 2020",
    "Regulation Number(s)": [
        "21 CFR 862.1155"
    ],
    "Regulation Name(s)": [
        "Human Chorionic Gonadotropin (HCG) Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Human Chorionic Gonadotropin (hCG)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)",
        "Plasma (Lithium heparin)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur\u00ae XP system"
    ],
    "Method(s)/Technology(ies)": [
        "2-site Sandwich immunoassay",
        "Direct chemiluminescent"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Diluent",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur Total hCG assay using direct chemiluminescent sandwich immunoassay for quantitative hCG determination in serum and plasma.",
    "Indications for Use Summary": "For in vitro diagnostic use in the quantitative determination of human chorionic gonadotropin (hCG) in serum or plasma (EDTA or lithium heparin) using the ADVIA Centaur XP system; intended as an aid in the early detection of pregnancy.",
    "fda_folder": "Clinical Chemistry"
}